Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis

Aim. To investigate rosuvastatin effects on oxidative stress (OS), endogenous inflammation and neoangiogenesis process in patients with systemic atherosclerosis (SA).Material and methods. In total, 46 SA patients (mean age 56,5±2,2 years) were divided into two groups, comparable by clinical and func...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. V. Shchukin, E. I. Seleznev, V. A. Dyachkov, E. A. Medvedeva, E. A. Surkova, А. E. Ryabov
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2009-08-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1811
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849250402370846720
author Yu. V. Shchukin
E. I. Seleznev
V. A. Dyachkov
E. A. Medvedeva
E. A. Surkova
А. E. Ryabov
author_facet Yu. V. Shchukin
E. I. Seleznev
V. A. Dyachkov
E. A. Medvedeva
E. A. Surkova
А. E. Ryabov
author_sort Yu. V. Shchukin
collection DOAJ
description Aim. To investigate rosuvastatin effects on oxidative stress (OS), endogenous inflammation and neoangiogenesis process in patients with systemic atherosclerosis (SA).Material and methods. In total, 46 SA patients (mean age 56,5±2,2 years) were divided into two groups, comparable by clinical and functional parameters. Group I (n=24) received standard therapy, while Group II (n=22) was administered standard therapy plus rosuvastatin (10 mg/d). In all participants, serum lipid profile, in vitro Cu-ion oxidation of serum and high-density lipoproteins (HDL), concentrations of 3-nitrotyrosine (3-NT), high-sensitive C-reactive protein (hs-CRP), and interleukin-6 (IL-6), activity of secretory phospholipase A2 Type IIA (secPHLA2-IIA), and VEGF and PIGF factor levels were measured.Results. Moderate doses of rosuvastatin significantly decreased serum and HDL oxidation — by 34% (р<0,01) and 37% (р<0,05), respectively. They also reduced the levels of 3-NT by 26% (р<0,05), hs-CRP — by 35% (р<0,05), and IL-6 — 26% (р<0,05). SecPHLA2-IIA activity decreased by 27% (р<0,05), VEGF level — by 28% (р<0,05), and PIGF level - by 43,5% (р<0,05).Conclusion. 3-NT and hs-CRP levels, together with secPHLA2-IIA activity, could be effective markers of systemic OS and endogenous inflammation in SA patients.
format Article
id doaj-art-b3e0a57685bd4eae9e7ea1e35bc58bb2
institution Kabale University
issn 1728-8800
2619-0125
language Russian
publishDate 2009-08-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-b3e0a57685bd4eae9e7ea1e35bc58bb22025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-08-018452571526Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosisYu. V. Shchukin0E. I. Seleznev1V. A. Dyachkov2E. A. Medvedeva3E. A. Surkova4А. E. Ryabov5Samara State Medical UniversitySamara State Medical UniversitySamara State Medical UniversitySamara State Medical UniversitySamara State Medical UniversitySamara State Medical UniversityAim. To investigate rosuvastatin effects on oxidative stress (OS), endogenous inflammation and neoangiogenesis process in patients with systemic atherosclerosis (SA).Material and methods. In total, 46 SA patients (mean age 56,5±2,2 years) were divided into two groups, comparable by clinical and functional parameters. Group I (n=24) received standard therapy, while Group II (n=22) was administered standard therapy plus rosuvastatin (10 mg/d). In all participants, serum lipid profile, in vitro Cu-ion oxidation of serum and high-density lipoproteins (HDL), concentrations of 3-nitrotyrosine (3-NT), high-sensitive C-reactive protein (hs-CRP), and interleukin-6 (IL-6), activity of secretory phospholipase A2 Type IIA (secPHLA2-IIA), and VEGF and PIGF factor levels were measured.Results. Moderate doses of rosuvastatin significantly decreased serum and HDL oxidation — by 34% (р<0,01) and 37% (р<0,05), respectively. They also reduced the levels of 3-NT by 26% (р<0,05), hs-CRP — by 35% (р<0,05), and IL-6 — 26% (р<0,05). SecPHLA2-IIA activity decreased by 27% (р<0,05), VEGF level — by 28% (р<0,05), and PIGF level - by 43,5% (р<0,05).Conclusion. 3-NT and hs-CRP levels, together with secPHLA2-IIA activity, could be effective markers of systemic OS and endogenous inflammation in SA patients.https://cardiovascular.elpub.ru/jour/article/view/1811atherosclerosisrosuvastatinoxidative stressendogenous inflammationneoangiogenesis
spellingShingle Yu. V. Shchukin
E. I. Seleznev
V. A. Dyachkov
E. A. Medvedeva
E. A. Surkova
А. E. Ryabov
Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis
Кардиоваскулярная терапия и профилактика
atherosclerosis
rosuvastatin
oxidative stress
endogenous inflammation
neoangiogenesis
title Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis
title_full Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis
title_fullStr Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis
title_full_unstemmed Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis
title_short Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis
title_sort rosuvastatin effects on systemic oxidative stress endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis
topic atherosclerosis
rosuvastatin
oxidative stress
endogenous inflammation
neoangiogenesis
url https://cardiovascular.elpub.ru/jour/article/view/1811
work_keys_str_mv AT yuvshchukin rosuvastatineffectsonsystemicoxidativestressendogenousinflammationandmainneoangiogenesisfactorsinpatientswithatherosclerosis
AT eiseleznev rosuvastatineffectsonsystemicoxidativestressendogenousinflammationandmainneoangiogenesisfactorsinpatientswithatherosclerosis
AT vadyachkov rosuvastatineffectsonsystemicoxidativestressendogenousinflammationandmainneoangiogenesisfactorsinpatientswithatherosclerosis
AT eamedvedeva rosuvastatineffectsonsystemicoxidativestressendogenousinflammationandmainneoangiogenesisfactorsinpatientswithatherosclerosis
AT easurkova rosuvastatineffectsonsystemicoxidativestressendogenousinflammationandmainneoangiogenesisfactorsinpatientswithatherosclerosis
AT aeryabov rosuvastatineffectsonsystemicoxidativestressendogenousinflammationandmainneoangiogenesisfactorsinpatientswithatherosclerosis